12
IRUS TotalDownloads
Altmetric
Repurposing fostamatinib to combat SARS-CoV-2-induced acute lung injury.
| File | Description | Size | Format | |
|---|---|---|---|---|
 Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.pdf | Published version | 200.81 kB | Adobe PDF | View/Open |
| Title: | Repurposing fostamatinib to combat SARS-CoV-2-induced acute lung injury. |
| Authors: | Tabassum, N Zhang, H Stebbing, J |
| Item Type: | Journal Article |
| Abstract: | A screen by Kost-Alimova et al.1 suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). |
| Issue Date: | 17-Nov-2020 |
| Date of Acceptance: | 1-Nov-2020 |
| URI: | http://hdl.handle.net/10044/1/88080 |
| DOI: | 10.1016/j.xcrm.2020.100145 |
| ISSN: | 2666-3791 |
| Start Page: | 1 |
| End Page: | 2 |
| Journal / Book Title: | Cell Reports Medicine |
| Volume: | 1 |
| Issue: | 8 |
| Copyright Statement: | © 2020 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| Sponsor/Funder: | Imperial College Healthcare NHS Trust- BRC Funding National Institute for Health Research |
| Funder's Grant Number: | RDB01 79560 NIHR-RP-011-053 |
| Publication Status: | Published |
| Conference Place: | United States |
| Online Publication Date: | 2020-11-17 |
| Appears in Collections: | Department of Surgery and Cancer Imperial College London COVID-19 Faculty of Natural Sciences |
This item is licensed under a Creative Commons License
